BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30664724)

  • 1. Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation.
    Fu H; Zhang X; Han T; Mo X; Wang Y; Chen H; Han W; Wang J; Wang F; Yan C; Zhang Y; Sun Y; Liu K; Huang X; Xu L
    Bone Marrow Transplant; 2019 Aug; 54(8):1310-1318. PubMed ID: 30664724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag.
    Tang C; Chen F; Kong D; Ma Q; Dai H; Yin J; Li Z; Chen J; Zhu X; Mao X; Wu D; Tang X
    J Hematol Oncol; 2018 Aug; 11(1):103. PubMed ID: 30115080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Eltrombopag for refractory thrombocytopenia in patients with allogeneic hematopoietic stem cell transplantation].
    Ma YR; Huang XJ; Mo XD; Han W; Yan CH; Chen Y; Ji Y; Chen YY; Wang Y; Zhang XH; Liu KY; Xu LP
    Zhonghua Xue Ye Xue Za Zhi; 2016 Dec; 37(12):1065-1069. PubMed ID: 28088971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploidentical peripheral blood stem cell transplantation: a single-center experience.
    Yan F; Lu N; Gu Z; Huang W; Wang S; Gao X; Dou L; Li F; Wang L; Li M; Liu D; Gao C
    Ann Hematol; 2022 Feb; 101(2):397-408. PubMed ID: 34735613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag for secondary failure of platelet recovery post-allogeneic hematopoietic stem cell transplant in children.
    Ali S; Gassas A; Kirby-Allen M; Krueger J; Ali M; Schechter T
    Pediatr Transplant; 2017 Sep; 21(6):. PubMed ID: 28653480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experience.
    Kilic Gunes E; Yigit Kaya S; Yaman F; Yeniay MK; Vural K; Comert M; Sevindik OG; Andic N; Dagdas S; Nizam Ozen I; Kaynar L; Yavasoglu F; Ozet G; Karakus V; Ayli M
    Leuk Res; 2024 May; 140():107484. PubMed ID: 38520796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience.
    Yaman Y; Elli M; Şahin Ş; Özdilli K; Bilgen H; Bayram N; Nepesov S; Anak S
    Pediatr Transplant; 2021 Aug; 25(5):e13962. PubMed ID: 33452850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem celltransplantation.
    Karataş A; Göker H; Demiroğlu H; Malkan ÜY; Velet M; Çınar OE; Erdoğdu B; Karadeniz M; Sayınalp N; Aksu S; Haznedaroğlu İC; Özcebe Oİ; Büyükaşık Y
    Turk J Med Sci; 2022 Apr; 52(2):413-419. PubMed ID: 36161632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin.
    Li Y; Kong F; Bai G; Jiang Y; Zhang W; Sun X; Sui X; Li Y; Ding M; Yuan D; Wang X; Fang X
    Front Immunol; 2024; 15():1340908. PubMed ID: 38650933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herombopag for the treatment of persistent thrombocytopenia following hematopoietic stem cell transplantation.
    Zhou M; Li T; Zhang P; Lai Y; Sheng L; Ouyang G
    Ann Hematol; 2024 May; 103(5):1697-1704. PubMed ID: 38536476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of eltrombopag for the treatment of poor graft function after hematopoietic stem cell transplantation in children.
    Uria-Oficialdegui ML; Alonso L; Benitez-Carabante MI; Renedo B; Oliveras M; Diaz-de-Heredia C
    Pediatr Transplant; 2021 Jun; 25(4):e14010. PubMed ID: 33742757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.
    Liesveld JL; Phillips GL; Becker M; Constine LS; Friedberg J; Andolina JR; Milner LA; DeBolt J; Smudzin T; Hyrien O; Erickson-Miller CL; Johnson BM; Dawson KL; Chen Y
    Biol Blood Marrow Transplant; 2013 Dec; 19(12):1745-52. PubMed ID: 24120380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of eltrombopag plus pulsed dexamethasone as first-line therapy for immune thrombocytopenia.
    Zhang L; Zhang M; Du X; Cheng Y; Cheng G
    Br J Haematol; 2020 Apr; 189(2):369-378. PubMed ID: 31943136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation.
    Tanaka T; Inamoto Y; Yamashita T; Fuji S; Okinaka K; Kurosawa S; Kim SW; Tanosaki R; Fukuda T
    Biol Blood Marrow Transplant; 2016 May; 22(5):919-24. PubMed ID: 26785333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children.
    Masetti R; Vendemini F; Quarello P; Girardi K; Prete A; Fagioli F; Pession A; Locatelli F
    Pediatr Blood Cancer; 2020 May; 67(5):e28208. PubMed ID: 32065469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children.
    Li S; Wu R; Wang B; Fu L; Zhu G; Zhou X; Ma J; Zhang L; Qin M
    J Pediatr Hematol Oncol; 2019 Jan; 41(1):38-41. PubMed ID: 30080752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag for treatment of thrombocytopenia-associated disorders.
    Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
    Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study.
    Ahmed S; Bashir Q; Bassett RL; Ullah F; Aung F; Valdez BC; Alousi AM; Hosing C; Kebriaei P; Khouri I; Marin D; Nieto Y; Olson A; Oran B; Qazilbash MH; Rezvani K; Mehta R; Shpall EJ; Ciurea S; Andersson BS; Champlin RE; Popat UR
    Am J Hematol; 2024 Apr; 99(4):562-569. PubMed ID: 38314663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.